Carella, A.M.Goldman, J.M.Martinelli, G.Melo, J.V.Perrotti, D.2015-05-172015-05-172011Haematologica: the hematology journal, 2011; 96(12):1737-17390390-60781592-8721http://hdl.handle.net/2440/91137Recent years have seen dramatic advances in deciphering the molecular pathogenesis of chronic myeloid leukemia (CML). This has resulted in the rapid development of many BCR-ABL1-specific tyrosine kinase inhibitors (TKI) which have improved 10-year survival to more than 80%. In this paper we focus on some future directions for CML biology and therapy.enCopyright © Ferrata Storti FoundationNeoplastic Stem CellsJournal article003002741010.3324/haematol.2011.0525710002985444000032-s2.0-82855164015183940